profit from every $100 of sales.
$0$100
Aurinia Pharmaceuticals
$16.62+0.97% today
+13.8% in 1 year
1-year low $13.951-year high $18.62
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $7.75 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Aurinia Pharmaceuticals sold, what it kept, and what it did with the cash.
Sales went from $134 million in 2022 to $283 million in 2025, with $287 million of profit last year.
SalesProfit
Aurinia Pharmaceuticals handed back 72% of the cash it generated last year.
Buybacks $98M
Free cash flow 2025$135M
Bought back its own shares$98M
Paid as dividends–
Cash vs. debt$80M vs. $75M
Aurinia Pharmaceuticals vs. similar companies
Aurinia Pharmaceuticals grows the fastest of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Aurinia Pharmaceuticals | 7.8× · Cheap | ||
 Vertex Pharmaceuticals | 35.3× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.1× · Fair price | ||
 CSL | 22.2× · Fair price |
AI analysis
An AI analyst reads Aurinia Pharmaceuticals's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 134 | 176 | 235 | 283 | |
| 128 | 161 | 207 | 250 | |
| -111 | -92 | 18 | 107 | |
| -104 | -63 | 32 | 138 | |
| -108 | -78 | 6 | 287 | |
| -0.76 | -0.54 | 0.04 | 2.07 | |
| 95.8% | 91.9% | 88.0% | 88.5% | |
| -83.2% | -52.2% | 7.8% | 37.6% | |
| -80.7% | -44.5% | 2.4% | 101.5% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 471 | 548 | 551 | 752 |
| Cash | 94 | 49 | 83 | 80 |
| Total debt | 8 | 98 | 79 | 75 |
| Total liabilities | 65 | 170 | 173 | 170 |
| 405 | 378 | 377 | 581 | |
| 142 | 143 | 146 | 139 | |
| -20.3% | -12.4% | 2.1% | 14.3% | |
| -26.7% | -20.6% | 1.5% | 49.4% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -80 | -33 | 44 | 136 | |
| 0 | 1 | 0 | 0 | |
| -80 | -34 | 44 | 135 | |
| Dividends paid | – | – | – | – |
| 0 | 0 | 40 | 98 | |
| – | – | – | – |
Valuation
- 7.8×
- 20.4×
- –
- 3.6×
- 7.9×
- 16.4×
- 16.1×
- 6.1%
- 12.9%
- 0.0%
Profitability
- 88.5%
- 37.6%
- 101.5%
- 54.2%
- 19.0%
- -6.9%
- 64.5%
- 41.2%
- 19.5%
- 11.5%
Growth
- +28.3%
- –
- +207.0%
- –
- +1.0%
Financial health
- 0.2×
- 0.12
- 9.5%
- 14.4×
- 5.55
- 5.01
- 0.41
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 10%of 948
Top 5%of 871
Top 6%of 560
Top 20%of 868
Top 16%of 985
What analysts expect
- Average price target
- $16.00
- Range
- $16.00 – $16.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | 0.25 | 0.18 | +38.9% |
| Feb 26, 2026 | 0.26 | 0.21 | +23.8% |
| Nov 4, 2025 | 0.23 | 0.16 | +43.8% |
| Jul 31, 2025 | 0.16 | 0.17 | −5.9% |
| May 12, 2025 | 0.16 | 0.08 | +100.0% |
| Feb 27, 2025 | 0.09 | 0.03 | +200.0% |
| Nov 7, 2024 | 0.10 | 0.02 | +566.7% |
| Aug 1, 2024 | 0.02 | 0.02 | +20.0% |
News
Aurinia settles Lupkynis patent litigation with TevaSeeking Alpha · Aug 19, 2026The newest story we have is from Aug 19, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
6/7Passes 6 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
70Pass
Benjamin Graham
67Pass
Philip Fisher
78Pass
Peter Lynch
100Pass
Joel Greenblatt
56No pass
Charlie Munger
69Pass
Terry Smith
62Pass
Questions about Aurinia Pharmaceuticals
Is Aurinia Pharmaceuticals a good stock to buy?
A strong, very profitable business, and the price looks low. 6 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Aurinia Pharmaceuticals AI analysis
What does Aurinia Pharmaceuticals do?
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. It is in Biotechnology.
Does Aurinia Pharmaceuticals pay a dividend?
No. Aurinia Pharmaceuticals does not pay a dividend at the moment; in 2025 it returned $98.2 million to shareholders by buying back its own shares.
Is Aurinia Pharmaceuticals stock halal?
Yes. Aurinia Pharmaceuticals passes our halal screen: its business is permitted and its debt is 3% of its market value, under the 30% limit. How we check
How has Aurinia Pharmaceuticals stock done over the past year?
Up 13.8% over the past twelve months, to $16.62. It traded between $13.95 and $18.62 and is 10.7% below its high.
Who are Aurinia Pharmaceuticals's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Aurinia Pharmaceuticals's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.